BNIP3 and colonic neoplasm: Zhang et al. examined 451 patients with unresectable colon cancer treated with FOLFIRI (5-FU, levofolinate, and irinotecan) plus bevacizumab in two phase III trials and demonstrated that some single-nucleotide polymorphisms in BNIP3 were predictors of satisfactory response to the regimen [31].